Durvalumab consolidates treatment breakthroughs: Significantly prolongs the survival of confined small cell lung cancer 26/09/2025
Retifanlimab-dlwr is used to treat metastatic or recurrent locally advanced Merkel cell carcinoma 21/09/2025
Immunotherapy combined with chemotherapy for the treatment of advanced gastric cancer/gastroesophageal junction adenocarcinoma: Analysis of the results of DURIGAST PHASE II trial 15/09/2025
The U.S. FDA accelerated the approval of Retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma 09/09/2025
Novel dual immunotherapy for the treatment of drug-resistant ovarian cancer, with a disease control rate of 67% 12/07/2023
MSS-type advanced colorectal cancer: The second-generation immune combination has been fast-tracked by the FDA 12/07/2023
